Float Short %

8.83

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

0.01

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

12.29

Target Price

17.5

Analyst Recom

1.08

Performance Q

70.48

Relative Volume

0.6

Beta

1.5

Ticker: OCUL

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-28	OCUL	12.09	0.13	0.05	38970
2025-07-29	OCUL	11.77	0.13	1.34	39166
2025-07-30	OCUL	11.65	0.15	0.01	39173
2025-07-31	OCUL	11.57	0.15	1.42	39059
2025-08-01	OCUL	11.91	0.15	0.06	39178
2025-08-04	OCUL	12.35	0.14	0.61	40345
2025-08-05	OCUL	11.99	0.18	0.01	41360
2025-08-06	OCUL	12.48	0.16	0.03	45841
2025-08-07	OCUL	12.3	0.15	0.01	47698
2025-08-08	OCUL	12.2	0.15	0.00	48695
2025-08-11	OCUL	12.56	0.15	0.02	49565
2025-08-12	OCUL	12.48	0.15	0.05	50275
2025-08-13	OCUL	12.49	0.15	0.53	50069
2025-08-14	OCUL	12.64	0.15	0.04	49741
2025-08-15	OCUL	12.62	0.15	0.03	49811
2025-08-18	OCUL	12.3	0.11	1.06	44865
2025-08-19	OCUL	12.15	0.12	0.04	45185
2025-08-20	OCUL	11.96	0.12	0.09	45381
2025-08-21	OCUL	12.12	0.12	0.13	45391
2025-08-22	OCUL	12.3	0.12	0.00	45454
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-28	OCUL	12.06	-36.5	-	-1.45
2025-07-29	OCUL	11.75	-36.5	-	-1.45
2025-07-30	OCUL	11.66	-36.5	-	-1.45
2025-07-31	OCUL	11.58	-36.5	-	-1.45
2025-08-01	OCUL	11.92	-36.5	-	-1.45
2025-08-04	OCUL	12.35	-36.5	-	-1.45
2025-08-05	OCUL	12.00	-36.5	-	-1.45
2025-08-06	OCUL	12.50	-36.5	-	-1.45
2025-08-07	OCUL	12.30	-71.8	-	-1.45
2025-08-08	OCUL	12.21	-71.8	-	-1.50
2025-08-11	OCUL	12.55	-70.4	-	-1.49
2025-08-12	OCUL	12.48	-70.4	-	-1.49
2025-08-13	OCUL	12.50	-70.4	-	-1.49
2025-08-14	OCUL	12.64	-70.4	-	-1.49
2025-08-15	OCUL	12.63	-70.4	-	-1.49
2025-08-18	OCUL	12.30	-70.4	-	-1.49
2025-08-19	OCUL	12.14	-70.4	-	-1.49
2025-08-20	OCUL	11.95	-70.4	-	-1.49
2025-08-21	OCUL	12.12	-70.4	-	-1.49
2025-08-22	OCUL	12.29	-70.4	-	-1.49
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-28	OCUL	-0.31	21.10	11.10
2025-07-29	OCUL	-0.31	21.10	11.10
2025-07-30	OCUL	-0.31	21.10	11.10
2025-07-31	OCUL	-0.31	21.10	11.10
2025-08-01	OCUL	-0.31	21.10	11.10
2025-08-04	OCUL	-0.31	21.46	11.10
2025-08-05	OCUL	-0.24	21.46	11.10
2025-08-06	OCUL	-0.24	21.46	11.10
2025-08-07	OCUL	-0.24	21.46	11.10
2025-08-08	OCUL	-0.22	21.46	10.16
2025-08-11	OCUL	-0.22	19.30	10.17
2025-08-12	OCUL	-0.22	19.30	8.82
2025-08-13	OCUL	-0.22	19.30	8.82
2025-08-14	OCUL	-0.22	19.30	8.82
2025-08-15	OCUL	-0.22	19.30	8.82
2025-08-18	OCUL	-0.22	18.69	8.82
2025-08-19	OCUL	-0.22	18.69	8.82
2025-08-20	OCUL	-0.22	18.69	8.82
2025-08-21	OCUL	-0.22	18.69	8.83
2025-08-22	OCUL	-0.22	18.69	8.83
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.39

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.38

Insider Transactions

-0.22

Institutional Transactions

18.69

Beta

1.5

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

49.4

Max Drawdown 5-Year %

-90.9

Target Price

17.5

P/E

Forward P/E

PEG

P/S

37.77

P/B

6.95

P/Free Cash Flow

EPS

-1.28

Average EPS Est. Cur. Y

-1.49

EPS Next Y. (Est.)

-1.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-382.51

Relative Volume

0.6

Return on Equity vs Sector %

-95.5

Return on Equity vs Industry %

-82.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

Ocular Therapeutix, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 274

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today

news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance

stock history OCUL – Ocular Therapeutix, Inc. invest stock market

stock prices OCUL premarket after hours

ticker OCUL fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: OCUL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y